Group | Treatment | Emax | Linear Regression of Concentration-Response Data | ||||
---|---|---|---|---|---|---|---|
R | Slope | Position | pD2 | EC50 | |||
mN/mm2 | nM | ||||||
Jejunum | |||||||
F344 | Placebo | 42 ± 3 | 0.98 | 44.9 ± 3.3 | 364.8 ± 23.9 | 7.00 | 98 |
HLA-B27 | Placebo | 22 ± 32-a | 0.97 | 37.5 ± 3.0 | 299.9 ± 20.12-a | 6.60 | 248 |
HLA-B27 | rhIL-11 | 31 ± 42-a 2-b | 0.98 | 45.1 ± 3.7 | 364.5 ± 26.62-b | 6.96 | 1082-b |
Colon | |||||||
F344 | Placebo | 30 ± 4 | 0.98 | 42.0 ± 3.1 | 343.5 ± 22.2 | 6.98 | 103 |
HLA-B27 | Placebo | 19 ± 22-a | 0.99 | 40.0 ± 2.6 | 327.6 ± 18.2 | 6.94 | 115 |
HLA-B27 | rhIL-11 | 26 ± 42-b | 0.98 | 41.5 ± 2.8 | 339.6 ± 19.7 | 6.98 | 104 |
Emax, maximal response to carbachol;R, linear regression coefficient; pD2, negative log of the concentration of carbachol producing 50% of the maximal response (EC50).
Analysis of variance of multiple regression lines:
↵2-a p < 0.05 compared with placebo-treated F344 rats;
↵2-b p < 0.05 compared with placebo-treated HLA-B27 rats.